NCT03501576 2026-02-11
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
Recruiting
Clinical Trials
3 trialsNCT02518555 2026-01-07
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT00596336 2017-04-12
CLLIFVAC
The Royal Bournemouth Hospital
Phase 2 Terminated